Showing 910 – 920 of 1159 results
-
Intuitive Surgical Inc Initiation
William Blair initiated research coverage of Intuitive Surgical, Inc. (ISRG $246.68), which offers an ecosystem of minimally invasive surgical products and services that are founded on its da Vinci robotic system.
-
The Trade Desk Inc Initiation
William Blair initiated research coverage of The Trade Desk, Inc. (TTD $79.93), a company providing programmatic marketing automation technologies, services, and products.
-
The Procter and Gamble Company Initiation
William Blair initiated research coverage of The Procter & Gamble Company (PG $153.59), a global leader in the consumer packaged goods industry.
-
Avid Bioservices Inc Initiation
William Blair initiated research coverage of Avid Bioservices, Inc. (CDMO $10.01), a contract development and manufacturing organization (CDMO) focused on biologics drug substance manufacturing.
-
RayzeBio Inc Initiation
William Blair initiated research coverage of RayzeBio, Inc. (RYZB $19.23), a clinical-stage radiopharmaceuticals company with actinium-225-based lead program RYZ101 in a Phase III trial in neuroendocrine tumors (NETs) and Phase Ib study in small-cell lung cancer (SCLC).
-
Klaviyo Inc Initiation
William Blair initiated research coverage of Klaviyo, Inc. (KVYO $32.89), a full stack marketing automation platform with robust data management and segmentation capabilities that largely serves SMB and midmarket retail businesses today.
-
Neumora Therapeutics Inc Initiation
William Blair initiated research coverage of Neumora Therapeutics, Inc. (NMRA $12.14), a company focused on developing novel therapies for high-unmet-need indications in psychiatry and neurodegenerative diseases.
-
Celsius Holdings Inc Initiation
William Blair initiated research coverage of Celsius Holdings, Inc. (CELH $162.02), a high-growth company that develops, processes, markets, sells, and distributes functional energy drinks and liquid supplements in the United States and abroad.
-
Cabaletta Bio Inc Initiation
William Blair initiated research coverage of Cabaletta Bio, Inc. (CABA $13.69), a clinical-stage company focused on the development and commercialization of first-in-class immune cell therapies for the treatment of severe autoimmune disorders.
-
Warby Parker Inc Initiation
William Blair initiated research coverage of Warby Parker, Inc. (WRBY $11.19), an omnichannel retailer of prescription glasses, contact lenses, and sunglasses across the United States and Canada.